First appeared in Associated Press
The discovery that a fake version of the widely used cancer
medicine Avastin is circulating in the United States is raising new fears that
the multibillion-dollar drug-counterfeiting trade is increasingly making
inroads in the U.S.
The criminal practice has largely been relegated to poor
countries with lax regulations. But with more medicines and drug ingredients
for sale in the U.S. being manufactured overseas, American authorities are
afraid more counterfeits will find their way into this country, putting
patients' lives at risk.
The Avastin discovery follows other recent instances in the
U.S. of counterfeiting, involving such drugs as Viagra, the cholesterol
medicine Lipitor and the weight-loss pill Alli.
"We do know there are counterfeits continuing to try
and make their way onto the U.S. supply chain," said Connie Jung, an
associate director in the Food and Drug Administration's office of drug
security.
The FDA announced Tuesday it is investigating fake vials of
Avastin that were sold to at least 19 doctors and clinics, including 16 sites
in California, two in Texas and one in Chicago. Tests showed the vials did not
contain the active ingredient in Avastin, which is given intravenously in
hospitals, clinics and doctors' offices to treat several types of cancer.
The contents of the vials are still being analyzed, and the
FDA said it has not received any reports of patients who were harmed.
FDA officials said the counterfeit Avastin was imported from
Britain and distributed by Volunteer Distribution, a wholesaler based in
Gainesboro, Tenn. British regulators notified the FDA about the products in
December, but the agency didn't confirm they were fake until last week.
The FDA gave assurances Wednesday that the U.S. remains one
of the most secure pharmaceutical markets in the world. But the news sent
cancer doctors scrambling to check their records.
Mary Mathias, a nurse who orders drugs for one doctor on the
FDA list - Dr. Phillip L. Chatham in Granada Hills, Calif., - said they had
stopped using the company in question at least a year ago.
Because Avastin treatments are spaced one to two weeks
apart, it is not likely that someone would get more than one infusion from the
same vial. And because these are people facing a life-threatening disease, it
is hard to say whether missing one treatment with the real drug would
compromise their care.
Gauging harm from a counterfeit cancer treatment is nearly
impossible, said Dr. Robert C. Young, former president of the Fox Chase Cancer
Center in Philadelphia and now a consultant to cancer centers.
A colon cancer patient, for example, might receive 18 to 20
Avastin infusions over six months. Missing one dose seems unlikely to have a
dramatic effect on survival odds, but it's not provable either way because
cancer's course and a patient's response to treatment are not predictable, he
said.
Counterfeits have traditionally been more of a concern in
developing regions like Asia and Latin America, where as many as 30 percent of
drugs sold are fake, according to the World Health Organization. The group
estimates just 1 percent of drugs dispensed in the U.S. and other developed
nations are fake.
But incidents of counterfeiting reported by drugmakers have
increased steadily over the decade to more than 1,700 worldwide last year,
though only 6 percent of those were in the U.S. There are few reliable
estimates on the value of the global counterfeit drug trade, though most place
it in the tens of billions.
Counterfeiting has become more prevalent as pharmaceutical
supply chains increasingly stretch across continents. Over 80 percent of the
active ingredients used in U.S. pharmaceuticals are now manufactured overseas,
according to a recent congressional report, and experts say this has made it
easier to move counterfeit products into this country.
"With today's transportation networks, it's no longer a
stretch to move these materials from a source in Pakistan or India to the
U.S." said Tom Kubic, president of Pharmaceutical Security Institute, a
trade association set up by two dozen pharmaceutical companies.
In 2005, federal prosecutors indicted 11 employees of a
Missouri business on charges of conspiring to sell $42 million in counterfeit
Lipitor. It was manufactured in Costa Rica and illegally imported to the U.S.,
where it was sold to wholesalers.
Industry experts also say a combination of big profits and
low penalties has made drug counterfeiting an increasingly attractive business
for criminals in the U.S. and abroad.
A single vial of Avastin sells for $2,400, and the drug had
nearly $2.7 billion in U.S. sales last year, while the sentence for drug
counterfeiting in the United States is about three years in prison. That
compares with 15 years for counterfeiting money.
John Clark, head of global security for Pfizer Inc., said
counterfeiters can make several million dollars quickly and, if they're caught,
get off with as little as six months in jail. He also said counterfeiters can
set up an operation at a fairly low cost - perhaps $50,000, including about
$20,000 for a pill press.
"It's a no-brainer for criminal organizations that it's
worth a gamble," Clark said.
Clark said Pfizer's anti-counterfeiting team around the
world has seen a number of fake vaccines and biologic drugs sold in developing
countries, not just pill-based drugs.
"They're getting much more sophisticated," often
getting ahold of legitimate vials that had held such medicines, from patients,
trash cans or recycling operations, and then filling them with oil or water.
